NXTC
NextCure, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.82
−0.26%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 283.0K | 2.2M | — | — | — |
| Gross Profit | (283.0K) | (2.2M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 27.2M | 44.9M | 41.5M | 47.9M | 54.2M |
| SG&A Expense | 11.6M | 12.7M | 15.7M | 19.7M | 21.7M |
| General & Admin Expense | 11.6M | 12.7M | 15.7M | 19.7M | 21.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 4.8M | (2.2M) | 2.5M | — | — |
| Total Operating Expenses | 43.6M | 55.4M | 59.7M | 67.6M | 75.9M |
| Cost and Expenses | 43.9M | 57.6M | 59.7M | 67.6M | 75.9M |
| Operating Income (EBIT) | (43.9M) | (57.6M) | (59.7M) | (67.6M) | (75.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | 1.2M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | 1.2M |
| Other Non-Op Income/Expense | 1.2M | 1.8M | 4.1M | 4.9M | 1.2M |
| Non-Operating Income (excl Interest) | (1.2M) | (1.8M) | (2.5M) | (4.9M) | (1.2M) |
| EBT (Pre-Tax Income) | (42.7M) | (55.8M) | (55.7M) | (62.7M) | (74.7M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (42.7M) | (55.8M) | (55.7M) | (62.7M) | (74.7M) |
| Earnings from Cont. Ops | (42.7M) | (55.8M) | (55.7M) | (62.7M) | (74.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (42.7M) | (55.8M) | (55.7M) | (62.7M) | (74.7M) |
| Per Share | |||||
| Basic EPS | ($10.58) | ($19.65) | ($23.88) | ($27.04) | ($32.32) |
| Diluted EPS | ($10.58) | ($19.65) | ($23.88) | ($27.04) | ($32.32) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 5.3M | 2.8M | 2.3M | 2.3M | 2.3M |
| Diluted Shares Outstanding | 5.3M | 2.8M | 2.3M | 2.3M | 2.3M |
| Profitability Metrics | |||||
| EBITDA | (41.6M) | (53.7M) | (54.3M) | (59.0M) | (70.6M) |
| D&A | 1.2M | 2.2M | 2.9M | 3.7M | 4.1M |
| EBIT | (42.7M) | (55.8M) | (57.2M) | (62.7M) | (74.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026